Please login to the form below

Not currently logged in
Email:
Password:

Medivation

This page shows the latest Medivation news and features for those working in and with pharma, biotech and healthcare.

Pfizer names next CEO as Read retires

Pfizer names next CEO as Read retires

One M&A deal that did go through was the $14bn acquisition of Medivation in 2016, though many analysts say the big pharma company overpaid for the firm and its oncology

Latest news

More from news
Approximately 14 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    Only August 2016 ($21.4bn, including $14bn for the Pfizer Medivation deal) came close. ... Excluding the Shire-Baxalta and Pfizer-Medivation deals, the figure for total (disclosed) upfront payments typically ranges between $1-6bn per month.

  • Deal Watch August 2016 Deal Watch August 2016

    So the conclusion is that Pfizer is mainly expecting to generate value from Medivation's late stage oncology programme. ... Sanofi sought to take control of Medivation's board using a paper vote.

  • Deal Watch May 2016 Deal Watch May 2016

    on. Following its rejection of the $9.3bn [$52.5 per share in cash, 36% premium] on the table from Sanofi, Medivation is now open to bids, encouraging competition. ... In the light of this, Sanofi has elected to go hostile and has filed with the SEC

  • Deal Watch April 2016 Deal Watch April 2016

    Sanofi would like to merge with Medivation as it makes “strong strategic sense”. ... Unfortunately the Medivation CEO, David Hung, was not interested in a meeting or even hearing Sanofi's proposal.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Licence. 700. BioMarin. Medivation. Talazoparib a PARP inhibitor in P3 for BRCA mutated breast cancer.

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics